New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week
BioSpace,
16 min read Significant proteinuria reduction maintained at one year, regardless of immunosuppressant use or baseline…
